This study aimed to investigate the longer‐term effects of secukinumab 150 mg on fatigue in patients with ankylosing spondylitis (AS) in MEASURE 1 (up to 3 years) and MEASURE 2 (up to 2 years). Patients with active AS were randomized to secukinumab or placebo in MEASURE 1 (10 mg/kg intravenous [IV] followed by 150 mg subcutaneous [SC]) and MEASURE 2 (150 mg SC).
Patients were naive or had an inadequate response/intolerance to tumor necrosis factor inhibitors (anti‐TNF‐naive/ anti‐TNF‐IR). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) scale. Relationships between fatigue response and baseline characteristics and clinical/laboratory variables were explored. Significant improvements in FACIT‐F scores from baseline were observed with secukinumab across both studies versus placebo at week 16 (P < 0.05). Improvements were sustained through week 156 (MEASURE 1)/week 104 (MEASURE 2). Fatigue responses were achieved by 75.6% of patients receiving secukinumab at week 156 (MEASURE 1) and 81.4% at week 104 (MEASURE 2); these results were consistent in both anti‐TNF‐naive (74.3% and 84.6%) and anti‐TNF‐IR (81.3% and 75.0%) patients.
In conclusion, Secukinumab provided rapid and sustained improvements in fatigue for up to 3 years, regardless of prior anti‐TNF exposure.
Ref: https://onlinelibrary.wiley.com/doi/10.1002/acr.24517
